Connexion
Connexion
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Inscription
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VALNEVA SE

(VLA)
  Rapport
Temps réel Euronext Paris  -  17:35:45 03/02/2023
6.550 EUR   +0.61%
25/01Valneva : plus forte baisse du SBF 120 à la clôture du mercredi 25 janvier 2023 -
AO
25/01Valneva : plus forte baisse du SBF 120 à la mi-séance du mercredi 25 janvier 2023
AO
16/01Paris atone, Wall Street absente
AW
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur VALNEVA SE
03/01Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical S..
02/01Valneva's COVID-19 Booster Shot Shows Only Marginally Higher Neutralizing Antibody Resp..
2022Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
2022Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
2022Certain Stock Options of Valneva SE are subject to a Lock-Up Agreement Ending on 29-DEC..
2022Certain Equity Warrants of Valneva SE are subject to a Lock-Up Agreement Ending on 29-D..
2022Certain Ordinary Shares of Valneva SE are subject to a Lock-Up Agreement Ending on 29-D..
2022Sector Update: Health Care Stocks Mixed Premarket Friday
2022Fresh Inflation Data Eyed as Exchange-Traded Funds, Equity Futures Edge Higher Premarke..
2022Valneva Says it Completed Rolling US Regulatory Submission for One-Shot Chikungunya Vac..
2022Bolsa de Madrid: Todavía en modo ciclotímico
2022Valneva Finalizes Biologics License Submission With US FDA For Chikungunya Vaccine
2022Valneva makes U.S. regulatory submission for one-shot chikungunya vaccine
2022Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Ca..
2022Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Ca..
2022Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Ca..
2022Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and O..
2022Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and O..
2022Valneva COVID-19 Vaccine Reportedly Not Recommended by French Regulator
2022French Public Health Body Snubs Valneva in COVID-19 Vaccine Strategy
2022Valneva shares fall as French health body advises against its COVID-19 vaccine
2022Valneva : Advances in the development of a single-shot live-attenuated chikungunya vaccine..
2022Valneva SE Reiterates Revenue Guidance for the Year 2022
2022Valneva : Whole-cell inactivated platforms (Valneva Breakfast Symposium Presentation at th..
2022Inactivated Whole Cells Platform : the importance of choosing the right adjuvant, as illus..
2022Valneva Hosts Investor Day in New York City
2022Valneva Hosts Investor Day in New York City
2022EMA Publishes Updated Information On COVID-19 Vaccine Valneva, With Increase In Its App..
2022Ema: ema published updated information on covid-19 vaccine valne…
2022Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday
2022Sector Update: Health Care
2022Valneva Says Chikungunya Vaccine Candidate Shows 99% Seroresponse Rate After 12 Months
2022Valneva Shares Gain After Positive Vaccine Trial Results
2022EN DIRECTO DESDE LOS MERCADOS: Amazon, Apple, Valneva, Bén..
2022Valneva To Complete US FDA Application For Chikungunya Vaccine Candidate By 2022-end
2022Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya..
2022Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya..
2022Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya..
2022Strong Eurozone Manufacturing Data Pushes European Bourses to Close Mostly Higher
2022Pfizer, Valneva Say Lyme Disease Vaccine Candidate Shows Antibody Levels Remain Above B..
2022Valneva, Pfizer Tout Six-month Antibody Persistence Data for Lyme Disease Vaccine Candi..
2022Valneva-Pfizer's Lyme Disease Jab Continues To Provide Protection Six Months Post-vacci..
2022Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo..
2022Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo..
2022Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults fo..
2022Valneva to Host Investor Day in New York City
2022Valneva to Host Investor Day in New York City
2022Vaccine Developer Valneva Appoints New Chief Commercial Officer
2022Valneva Appoints Dipal Patel as Chief Commercial Officer
2022Valneva Appoints Dipal Patel as Chief Commercial Officer
2022ValnevaSE Appoints Dipal Patel as Chief Commercial Officer
2022Jobkahlschlag bei Corona-Impfstoffhersteller Valneva
2022Valneva Plans Workforce Reduction of Up to 25% in Restructuring Move
2022Bolsa de Madrid: ¿Feliz cumpleaños, bitcoin?
2022French drugmaker Valneva to cut 20%-25% of workforce
2022Valneva SE Reports Earnings Results for the Nine Months Ended September 30, 2022
2022Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
2022Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
2022Valneva SE Reiterates Earnings Guidance for the Fiscal 2022
2022Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Confer..
2022Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Confer..
2022Chikungunya : Phase 3 Clinical Development of a Single-shot Live-Attenuated Vaccine (Prese..
2022One Step Closer To A Chikungunya Vac : update on Valneva's live-attenuated vaccine candida..
2022Europäische Staatsanwaltschaft untersucht Kauf der Corona-Impfstoffe
2022One Step Closer To A Chikungunya Vac : update on Valneva's live-attenuated vaccine candida..
2022Bolsa de Madrid: Un rebote semanal engañoso
2022Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientif..
2022Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientif..
2022Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientif..
2022Bolsa de Madrid: Los planetas se alinean a toda prisa
2022Valneva Raises $103 Million to Advance Lyme Disease, Chikungunya Vaccine Candidates; Sh..
2022Valneva Announces Closing of Upsized €102.9 Million Global Offering
2022Valneva Announces Closing of Upsized €102.9 Million Global Offering
2022Valneva : Document AMF CP. 2022E864499
2022Valneva : Document AMF CP. 2022E864246
2022Valneva Prices Upsized Global Offering of $99.9 Million of Ordinary Shares and ADSs
2022Bolsa de Madrid: Inversores en posición lateral de seguridad
2022Valneva Prices Upsized $101 Million Global Offering to Fund Vaccines Developments
2022Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shar..
2022Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shar..
2022Valneva SE announced that it expects to receive funding from Deep Track Capital, LP
2022Sector Update: Health Care Stocks Decline Pre-Bell Thursday
2022Valneva to Raise $40 Million via Global Offering
2022Valneva Plans $40 Million Capital Raise From Global Share Offering
2022Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of ..
2022Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of ..
2022Valneva Says It Is in Active Discussions With Prospective Partner to Develop Second-Gen..
2022Bolsa de Madrid: El elefante en la habitación
2022Valneva In Talks With Potential Partner For Development Of Second-generation COVID-19 V..
2022Valneva in talks with potential partner on second-gen COVID-19 vaccines
2022Talks on second-gen COVID vaccine could fail, Valneva warns
2022Valneva Provides Further Update on its COVID-19 Activities
2022Valneva Provides Further Update on its COVID-19 Activities
2022Bolsa de Madrid: No está yendo muy bien
2022Valneva : Document AMF CP. 2022E862347
2022Valneva : Document AMF CP. 2022E861835ANN
2022Valneva : Document AMF CP. 2022E861835
2022Aktien Europa: Schwächer - Immobilienwerte unter Druck
2022Sector Update: Health Care Stocks Largely Resist Late Buying Support
2022Sector Update: Health Care Stocks Retreating to Begin New Week